Literature DB >> 12202660

Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status.

Charles L Bennett1, Douglas K Price, Simon Kim, Dachao Liu, Borko D Jovanovic, Derek Nathan, Margaret E Johnson, Jeffrey S Montgomery, Kelly Cude, Justin C Brockbank, Oliver Sartor, William D Figg.   

Abstract

PURPOSE: To evaluate (1) whether there were racial differences in the androgen receptor gene CAG repeat length and in clinical or laboratory attributes of prostate cancer at the time of diagnosis; (2) whether there were differences in race, Gleason score, prostate-specific antigen (PSA) level, and stage at diagnosis by androgen receptor gene CAG repeat length; and (3) whether sociodemographic, clinical, and laboratory based factors might be associated with advanced-stage prostate cancer. To our knowledge, our study is the first to report on CAG repeat lengths in a cohort of prostate cancer patients, which includes large numbers of African-American men.
METHODS: CAG repeat lengths on the androgen receptor gene were evaluated for 151 African-American and 168 white veterans with prostate cancer. The chi(2) test, t test, and logistic regression analyses were used to evaluate the associations between CAG repeat lengths and race, stage, histologic grade, and PSA levels at diagnosis.
RESULTS: The mean age of the cohort at the time of diagnosis was 68.7 years. At presentation, 42.0% had stage D prostate cancer, 26.5% had Gleason scores of 8 to 10, and 53.0% had PSA levels >/= 10 ng/dL. Mean androgen receptor gene CAG repeat length for white veterans was 21.9 (SD, 3.5) versus 19.8 (SD, 3.2) for African-American veterans (P =.001). Men with shorter CAG repeats were more likely to have stage D prostate cancer (P =.09) but were not more likely to have a higher PSA concentration or Gleason score.
CONCLUSION: In this cohort of men with prostate cancer, short CAG repeat length on the androgen receptor gene was associated with African-American race and possibly with higher stage but not with other clinical or pathologic findings.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202660     DOI: 10.1200/JCO.2002.11.085

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

Review 1.  TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.

Authors:  Cindy Ke Zhou; Denise Young; Edward D Yeboah; Sally B Coburn; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Shelley Niwa; Ann Truelove; Judith Welsh; James E Mensah; Robert N Hoover; Isabell A Sesterhenn; Ann W Hsing; Shiv Srivastava; Michael B Cook
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

Review 2.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  Cansu Karakas; Cassie Wang; Fangming Deng; Hongying Huang; Dongwen Wang; Peng Lee
Journal:  Am J Clin Exp Urol       Date:  2017-11-09

3.  Race and socioeconomic status are independently associated with benign prostatic hyperplasia.

Authors:  Jay H Fowke; Harvey J Murff; Lisa B Signorello; Lars Lund; William J Blot
Journal:  J Urol       Date:  2008-09-18       Impact factor: 7.450

4.  Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men.

Authors:  Jay H Fowke; Heather Munro; Lisa B Signorello; William J Blot; David F Penson
Journal:  J Gen Intern Med       Date:  2011-07-01       Impact factor: 5.128

5.  MiRNA 26a expression in a novel panel of African American prostate cancer cell lines.

Authors:  Shaniece C Theodore; Johng S Rhim; Timothy Turner; Clayton Yates
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

Review 6.  Prostate cancer in men of African origin.

Authors:  Kathleen F McGinley; Kae Jack Tay; Judd W Moul
Journal:  Nat Rev Urol       Date:  2015-12-31       Impact factor: 14.432

7.  LHRH-conjugated lytic peptides directly target prostate cancer cells.

Authors:  Clayton Yates; Starlette Sharp; Jacqueline Jones; Daphne Topps; Mathew Coleman; Ritu Aneja; Jesse Jaynes; Timothy Turner
Journal:  Biochem Pharmacol       Date:  2010-09-30       Impact factor: 5.858

Review 8.  MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans.

Authors:  J Jones; W Grizzle; H Wang; C Yates
Journal:  Biotech Histochem       Date:  2013-08-01       Impact factor: 1.718

9.  Evidence for molecular differences in prostate cancer between African American and Caucasian men.

Authors:  Francesca Khani; Juan Miguel Mosquera; Kyung Park; Mirjam Blattner; Catherine O'Reilly; Theresa Y MacDonald; Zhengming Chen; Abhishek Srivastava; Ashutosh K Tewari; Christopher E Barbieri; Mark A Rubin; Brian D Robinson
Journal:  Clin Cancer Res       Date:  2014-07-23       Impact factor: 12.531

Review 10.  Minireview: the molecular and genomic basis for prostate cancer health disparities.

Authors:  Isaac J Powell; Aliccia Bollig-Fischer
Journal:  Mol Endocrinol       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.